Event Type
Disclosure
Mandatory
Variant
8-K
. Entry Into a Material Definitive Agreement On December 30, 2025, Lixte Biotechnology Holdings, Inc., a Delaware corporation (the “Company”), entered into a Sh
Unregistered Sales of Equity Securities. The disclosure set forth above in Item 1.01 of this Form 8-K relating to exchange of the Series C Shares for Common Sto
Financial Statements and Exhibits (d) Exhibits. The following exhibits are filed herewith. Exhibit Number Description 10.1 Share Exchange Agreement dated Decemb